Drug‐Drug Interaction between Oral Zamicastat and Continuous Epoprostenol Infusion at Steady‐State Conditions in Healthy Subjects
- 24 June 2024
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (11) , 1361-1372
Abstract
This study intended to evaluate the interactions between zamicastat and epoprostenol in healthy human subjects. This was a single‐center, open‐label, two‐period study. In period 1, epoprostenol 8 ng/kg/min was administered alone. In period 2, epoprostenol 8 ng/kg/min was administered following an 8‐day treatment with zamicastat. Since the initial dose of epoprostenol showed to be insufficiently tolerated, it was decreased to 6 ng/kg/min. Blood samples were collected to determine the metabolites of epoprostenol and concentrations of zamicastat and its metabolites. A total of 54 subjects were enrolled and data from 28 subjects were available for pharmacokinetic analysis. The epoprostenol plus zamicastat‐to‐epoprostenol geometric means ratio (GMR) and corresponding 90% confidence interval (CI) for Cav,ss and area under the plasma concentration–time curve from time 0 up to 16 h at steady state (AUC0‐16,ss) of the metabolites of epoprostenol were within the acceptance bioequivalence range (80.00%‐125.00%). The intrasubject coefficient of variation (ISCV) was below 10% for both parameters, on both metabolites. For zamicastat AUC0‐τ,ss, the zamicastat plus epoprostenol‐to‐zamicastat GMR and corresponding 90% CI were within the bioequivalence acceptance range, while for zamicastat Cmax,ss, the lower limit of the 90% CI was slightly below the acceptance range. For zamicastat metabolites, Cmax,ss and AUC0‐τ,ss and the zamicastat plus epoprostenol‐to‐zamicastat GMR were below the acceptance bioequivalence range. ISCV was between 30% and 41% for Cmax,ss and between 21% and 41% for AUC0‐τ,ss, for zamicastat and both metabolites. This study showed that the administration of zamicastat did not significantly modify the cardiovascular effects of epoprostenol and that the interactions between zamicastat and epoprostenol are not expected to be clinically relevant.Keywords
This publication has 14 references indexed in Scilit:
- AN INTEGRATED ASSESSMENT OF PHARMACOKINETICS AND PHARMACODYNAMICS OF ZAMICASTAT: A DOPAMINE Β-HYDROXYLASE INHIBITOR IN HEALTHY VOLUNTEERSChest, 2021
- Abstract 14740: Sympathetic Down-regulation With Zamicastat Reduces Arrhythmogenicity in Isolated Hearts From Rats With Pulmonary HypertensionCirculation, 2020
- Zamicastat is a noncompetitive Dopamine‐β‐hydroxylase inhibitor that modulates sympathetic nervous system activityThe FASEB Journal, 2020
- Pulmonary arterial hypertension: pathogenesis and clinical managementBMJ, 2018
- Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in ratEuropean Journal of Pharmacology, 2014
- Comparative Pharmacokinetic, Pharmacodynamic, Safety, and Tolerability Profiles of 3 Different Formulations of Epoprostenol Sodium for Injection in Healthy MenClinical Therapeutics, 2013
- Increased Sympathetic Nerve Activity in Pulmonary Artery HypertensionCirculation, 2004
- Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary HypertensionCirculation, 2000
- Catecholamine modulatory effects of nepicastat (RS‐25560‐197), a novel, potent and selective inhibitor of dopamine‐β‐hydroxylaseBritish Journal of Pharmacology, 1997
- Prostacyclin metabolites in human plasmaClinical Pharmacology & Therapeutics, 1981